DAKLINZA
Total Payments
$2.1M
Transactions
238
Doctors
103
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $27.72 | 1 | 1 |
| 2023 | $24.24 | 2 | 2 |
| 2022 | $58.71 | 4 | 4 |
| 2021 | $164.64 | 15 | 13 |
| 2020 | $2,099 | 9 | 8 |
| 2019 | $6,183 | 15 | 13 |
| 2018 | $428,154 | 64 | 19 |
| 2017 | $1.7M | 128 | 45 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 131 | 99.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 2 | 0.3% |
| Consulting Fee | $2,875 | 1 | 0.1% |
| Food and Beverage | $1,339 | 104 | 0.1% |
Payments by Type
Research
$2.1M
131 transactions
General
$10,214
107 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HCV TARGET HCV Therapeutic Registry and Research Network A Longitudinal Observational Study | E.R. Squibb & Sons, L.L.C. | $1.1M | 0 |
| Phase III Long Term Follow Up | E.R. Squibb & Sons, L.L.C. | $613,164 | 0 |
| A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection | E.R. Squibb & Sons, L.L.C. | $187,494 | 0 |
| Phase III Peri Transplant DCV SOF | E.R. Squibb & Sons, L.L.C. | $119,576 | 0 |
| Phase III Long Term Follow-Up | E.R. Squibb & Sons, L.L.C. | $77,798 | 0 |
| Phase II Retreatment for SOC Non Responders | E.R. Squibb & Sons, L.L.C. | $20,719 | 0 |
| Ph IIA NS5A PSI7977 Combo | E.R. Squibb & Sons, L.L.C. | $10,584 | 0 |
| A Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir SOF and Ribavirin RBV for 12 or 24 Weeks in Subjects with Chronic Hepatitis C Infection Genotype 3 | E.R. Squibb & Sons, L.L.C. | $5,000 | 0 |
| Phase III Peri-Transplant DCV SOF | E.R. Squibb & Sons, L.L.C. | $2,000 | 0 |
| Phase III Genotype 3 naive, DCV SOF | E.R. Squibb & Sons, L.L.C. | $1,000 | 0 |
| Phase III Genotype 3 naive DCV SOF | E.R. Squibb & Sons, L.L.C. | $985.00 | 0 |
Top Doctors Receiving Payments for DAKLINZA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Downingtown, PA | $16.39 | 1 |
| Francis Brennan | — | Downingtown, PA | $16.39 | 1 |
| , M.D | Hematology & Oncology | Palos Heights, IL | $15.97 | 1 |
| , MD | Cardiovascular Disease | Florham Park, NJ | $15.92 | 1 |
| Sargis Khoobiar | — | Florham Park, NJ | $15.92 | 1 |
| , M.D | Vascular Surgery | La Jolla, CA | $15.91 | 1 |
| , MD | Family Medicine | La Jolla, CA | $15.91 | 1 |
| John Pellegrino | Family Medicine | Williamsport, PA | $14.60 | 1 |
| , M.D | Cardiovascular Disease | Hamilton, NJ | $14.45 | 1 |
| , MD | Cardiovascular Disease | Lawrenceville, NJ | $14.45 | 1 |
| , MD | Cardiovascular Disease | Hamilton, NJ | $14.45 | 1 |
| , DO | Cardiovascular Disease | Hamilton, NJ | $14.45 | 1 |
| , MD | Interventional Cardiology | Columbus, OH | $14.01 | 1 |
| , DO | Internal Medicine | Columbus, OH | $14.01 | 1 |
| , D.O | Cardiovascular Disease | Columbus, OH | $14.01 | 1 |
| Kevin Stiver | Internal Medicine | Columbus, OH | $14.01 | 1 |
| , MD, MPM | Internal Medicine | Pittsburgh, PA | $13.58 | 1 |
| , MD | Cardiovascular Disease | New Providence, NJ | $13.33 | 1 |
| , DO | Pulmonary Disease | Waterloo, IA | $13.27 | 1 |
| , MD | Pulmonary Disease | Waterloo, IA | $13.27 | 1 |
| , M.D | Interventional Cardiology | Columbus, OH | $13.14 | 1 |
| , M. D | Specialist | Ocala, FL | $13.07 | 1 |
| , M.D | Cardiovascular Disease | Horsham, PA | $13.04 | 1 |
| , M.D | Cardiovascular Disease | Horsham, PA | $13.04 | 1 |
| , D.O | Internal Medicine | Horsham, PA | $13.04 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 103
- Transactions 238
About DAKLINZA
DAKLINZA is a drug associated with $2.1M in payments to 103 healthcare providers, recorded across 238 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2024. In 2024, $27.72 was paid across 1 transactions to 1 doctors.
The most common payment nature for DAKLINZA is "Unspecified" ($2.1M, 99.5% of total).
DAKLINZA is associated with 11 research studies, including "HCV TARGET HCV Therapeutic Registry and Research Network A Longitudinal Observational Study" ($1.1M).